National Institute for Health and Care Excellence (NICE)

Haemophilia
#CSL #Gene therapy #Haemophilia #National Institute for Health and Care Excellence (NICE)

UK health watchdog rejects gene therapy for haemophilia B

In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted a marketing authorisation by the UK Medicines… Read More

#News #Regulatory #Trending News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Cancer cell
#Cancer research #Chemotherapy #Drug development #National Institute for Health and Care Excellence (NICE) #Regulatory

Positive NICE recommendation for BRCAm ovarian cancer 

AstraZeneca UK announced that Lynparza (olaparib) is recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy.  BRCA1 and BRCA2 are… Read More

#Editor's Choice #News #Regulatory #Trending News

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell… Read More

#News #Regulatory #Trending News

Leukaemia
#Leukaemia #National Institute for Health and Care Excellence (NICE) #Regulatory #UK

UK regulator approves ‘significant advance’ in CLL treatment

The National Institute for Health and Care Excellence (NICE) has approved a combination of Imbruvica (ibrutinib) and venetoclax for all untreated chronic lymphocytic leukaemia (CLL) patients in England. The oral, fixed-duration combination treatment for adult CLL patients has been approved as first-line therapy and has been shown to be more… Read More

#News #Regulatory

Asthma inhaler
#Asthma #AstraZeneca #Clinical trial #National Institute for Health and Care Excellence (NICE) #NHS England

Add-on treatment for severe uncontrolled asthma approved 

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma… Read More

#News

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

Duchenne muscular dystrophy
#Muscular dystrophy #National Institute for Health and Care Excellence (NICE) #Paediatrics #PTC Therapeutics #Rare disease

Rare muscular dystrophy drug to be funded in England and Wales

The National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.   Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged two years and older… Read More

#News #Regulatory

Growing bacteria to create CAR therapy
#Cancer research #CAR-T #Immuno-oncology #Immunotherapy #Kite Pharma #National Institute for Health and Care Excellence (NICE) #NHS England #Oncology #UK

Ground-breaking CAR-T therapy approved in UK

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal… Read More

#News #Regulatory #Trending News

Multiple myeloma
#Cancer research #Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends triplet regimen for relapsed multiple myeloma

NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy.  Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More

#Cancer Research #News #Regulatory #Trending News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

Uterine fibroids
#Gedeon Richter #National Institute for Health and Care Excellence (NICE) #Phase III trial #Uterine fibroids #Women's health

NICE recommends first oral GnRH antagonist for uterine fibroids   

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.  The decision makes the relugolix combination therapy… Read More

#News

#Biomarkers #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research

NICE rejects prostate cancer drug due to cost of genetic testing

The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. The Institute of Cancer Research (ICR) has called the decision ‘disappointing’ and ‘frustrating’. It means that men in England and Wales… Read More

#Cancer Research #News #Trending News

Antibiotics
#Antimicrobial resistance (AMR) #Antimicrobials #National Institute for Health and Care Excellence (NICE)

Important milestone reached in UK’s AMR fight 

The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of two new antimicrobial drugs to be used as part of a subscription style model within the healthcare system.   NICE has evaluated cefiderocol and ceftazidime–avibactam as part of a project with… Read More

#News